ArticleJournal of clinical microbiology2003
Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey.
Article in Journal of clinical microbiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-tuberculous mycobacterial infections in mainland China and Taiwan: a systematic review and meta-analysis of epidemiology, species distribution, and drug resistance (2013-2024).Frontiers in public health · 2025Pooled it
- Predictors of developing Mycobacterium kansasii pulmonary disease within 1 year among patients with single isolation in multiple sputum samples: A retrospective, longitudinal, multicentre study.Scientific reports · 2018Trial
- Genomic-based genotype and drug susceptibility profile ofFrontiers in microbiology · 2025Article
- The Intriguing Pattern of Nontuberculous Mycobacteria in Bulgaria and Description ofInternational journal of molecular sciences · 2024Article
- Phylogenomic and genomic analysis reveals unique and shared genetic signatures ofMicrobial genomics · 2024Article
- Article
- Applications and advances in molecular diagnostics: revolutionizing non-tuberculous mycobacteria species and subspecies identification.Frontiers in public health · 2024Review
- Molecular Characterisation ofPathogens (Basel, Switzerland) · 2023Article
- Clinical and Microbiological Characteristics of Mycobacterium kansasii Pulmonary Infections in China.Microbiology spectrum · 2022Article
- Human pathogenicEmerging microbes & infections · 2021Article
- Determination of Clinical Characteristics ofAnnals of laboratory medicine · 2021Article
- Current Updates on Mycobacterial Taxonomy, 2018 to 2019.Journal of clinical microbiology · 2021Review
- Population genomics provides insights into the evolution and adaptation to humans of the waterborne pathogen Mycobacterium kansasii.Nature communications · 2021Article
- Pathogenic Determinants of theMicroorganisms · 2021Article
- A Murine Model ofFrontiers in microbiology · 2021Article
- Transposon mutagenesis in Mycobacterium kansasii links a small RNA gene to colony morphology and biofilm formation and identifies 9,885 intragenic insertions that do not compromise colony outgrowth.MicrobiologyOpen · 2020Article
- Ethambutol-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2020Article
- Comparative Genomic and Transcriptomic Analyses ofFrontiers in cellular and infection microbiology · 2020Article
- Molecular Identification, and Characterization ofInfection and drug resistance · 2020Article
- Added diagnostic value of 16S rRNA gene pan-mycobacterial PCR for nontuberculous mycobacterial infections: a 10-year retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several subtypes of Mycobacterium kansasii have been described, but their respective pathogenic roles are not clear. This study investigated the distribution of subtypes and the pathogenicity of M. kansasii strains (n = 191) isolated in Switzerland between 1991 and 1997. Demographic, clinical, and microbiological information was recorded from clinical files. Patients were classified as having an infection according to the criteria of the American Thoracic Society. Subtypes were defined by PCR-restriction enzyme analysis of the hsp65 gene. Subtype 1 comprised 67% of the isolates (n = 128), while subtypes 2 and 3 comprised 21% (n = 40) and 8% (n = 15), respectively. Other subtypes (subtypes 4 and 6 and a new subtype, 7) were recovered from only 4% of patients (n = 8). M. kansasii subtype 1 was considered pathogenic in 81% of patients, while M. kansasii subtype 2 was considered pathogenic in 67% of patients and other subtypes were considered pathogenic in 6% of patients. The majority of patients with M. kansasii subtype 2 were immunocompromised due to the use of corticosteroids (21% of patients) or coinfection with HIV (62.5% of patients). Subtyping M. kansasii may improve clinical management by distinguishing pathogenic from nonpathogenic subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.